Related Experiment Video
Updated: May 11, 2026

Use of the EpiAirway Model for Characterizing Long-term Host-pathogen Interactions
Published on: September 2, 2011
Recreating chronic respiratory infections in vitro using physiologically relevant models
Lucia Grassi1, Aurélie Crabbé2
1Laboratory of Pharmaceutical Microbiology, Ghent University, Belgium.
Abstract:
Despite the need for effective treatments against chronic respiratory infections (often caused by pathogenic biofilms), only a few new antimicrobials have been introduced to the market in recent decades. Although different factors impede the successful advancement of antimicrobial candidates from the bench to the clinic, a major driver is the use of poorly predictive model systems in preclinical research. To bridge this translational gap, significant efforts have been made to develop physiologically relevant models capable of recapitulating the key aspects of the airway microenvironment that are known to influence infection dynamics and antimicrobial activity in vivo In this review, we provide an overview of state-of-the-art cell culture platforms and ex vivo models that have been used to model chronic (biofilm-associated) airway infections, including air-liquid interfaces, three-dimensional cultures obtained with rotating-wall vessel bioreactors, lung-on-a-chips and ex vivo pig lungs. Our focus is on highlighting the advantages of these infection models over standard (abiotic) biofilm methods by describing studies that have benefited from these platforms to investigate chronic bacterial infections and explore novel antibiofilm strategies. Furthermore, we discuss the challenges that still need to be overcome to ensure the widespread application of in vivo-like infection models in antimicrobial drug development, suggesting possible directions for future research. Bearing in mind that no single model is able to faithfully capture the full complexity of the (infected) airways, we emphasise the importance of informed model selection in order to generate clinically relevant experimental data.
Insights
Developing better models for chronic respiratory infections is crucial for new antimicrobial drugs. Advanced cell culture and ex vivo models offer more accurate preclinical testing than standard methods.
Area of Science:
- Microbiology
- Pharmacology
- Translational Medicine
Background:
- Chronic respiratory infections, often biofilm-associated, lack effective treatments due to limited antimicrobial development.
- Poorly predictive preclinical models hinder the translation of antimicrobial candidates from research to clinical application.
- The airway microenvironment significantly influences infection dynamics and antimicrobial efficacy in vivo.
Purpose of the Study:
- To review advanced cell culture and ex vivo models for simulating chronic airway infections.
- To highlight the advantages of physiologically relevant models over standard biofilm methods.
- To discuss challenges and future directions for in vivo-like infection models in drug development.
Main Methods:
- Overview of air-liquid interface cultures.
- Description of 3D cultures using rotating-wall vessel bioreactors.
- Analysis of lung-on-a-chip and ex vivo pig lung models.
Main Results:
- These advanced models provide greater physiological relevance for studying chronic bacterial infections.
- Studies using these platforms have explored novel antibiofilm strategies.
- Physiologically relevant models improve the investigation of antimicrobial activity in simulated airway infections.
Conclusions:
- Advanced models like ALI cultures, 3D bioreactors, lung-on-a-chips, and ex vivo lungs offer improved preclinical insights.
- Widespread adoption of these in vivo-like models requires overcoming current challenges in antimicrobial drug development.
- Informed selection of appropriate models is essential for generating clinically relevant data for airway infections.
More Related Videos
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
10:30Author Spotlight: Developing a Microfluidic Lung-on-Chip Model for In-Depth Study of Human Immune Response and Infection Mechanisms
Published on: May 31, 2024